TrialAmerican journal of hematology2026

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Nancy L Bartlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.